Sarep­ta CEO Doug In­gram buys $2M batch of his biotech's stock; Ex­press Scripts ex­plor­ing ex­clu­sive gene ther­a­py deals

Sarep­ta’s shares $SRPT have climbed fast since Doug In­gram stepped in as CEO and had a chance to do some deals and reap the ben­e­fits of a promis­ing ear­ly-stage gene ther­a­py pro­gram. As we’ve not­ed be­fore, In­gram has a rich pay pack­age tied to the per­for­mance of the com­pa­ny’s stock. And he’s demon­strat­ing some per­son­al con­fi­dence by adding $2 mil­lion worth of shares in the biotech to his port­fo­lio. The stock pur­chase was out­lined in an SEC fil­ing, which has had some promi­nent dis­tri­b­u­tion this morn­ing on Twit­ter.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.